OraSure reels in $7.2M from HHS for rapid Ebola test

OraSure CEO Douglas Michels

OraSure Technologies ($OSUR) scored an additional $7.2 million from the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research Development Authority (BARDA) for its rapid Ebola test, building on a $10.4 million contract that it signed with BARDA in June. As part of the latest deal, OraSure will sell $1.5 million worth of OraQuick products to the HHS' Centers for Disease Control and Prevention (CDC) for field testing in West Africa. The Bethlehem, PA-based company will use funds to support FDA 510(k) clearance for its test. "The populations affected by Ebola are large, and current testing methods severely limit testing capacity. As such, we believe that the OraQuick Rapid Ebola Test will be an important tool in containing and controlling the Ebola outbreak," OraSure CEO Douglas Michels said in a statement. "We are grateful to both the CDC and BARDA for their continued support." Statement

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.